eprescribing of Chemotherapy The Leeds Experience Julie Mansell, Lead Chemotherapy Pharmacist, Leeds Cancer Centre
|
|
- Shavonne Harmon
- 5 years ago
- Views:
Transcription
1 eprescribing of Chemotherapy The Leeds Experience Julie Mansell, Lead Chemotherapy Pharmacist, Leeds Cancer Centre
2 Background at Leeds Teaching Hospitals SJUH Opmas 1993 Cookridge Design partners Chemocare 1995 Introduced to breast cancer clinic, gradual rollout Cookridge site oncology SJUH, haematology 60+ consultants 5000 patients per annum Oncology, haematology, BMT, trials including early phase Treatment given orally, day case, in-patient and ambulatory All chemotherapy prescribed using Chemocare
3 Improved safety 2006 Journal of Quality and Safety in Healthcare Effect of computerisation on the quality and safety of chemotherapy prescription Oncology centre in Lausanne Examined chemotherapy errors before and after implementation Classification of errors Major = drug name, dose, route of administration Before 141 errors in 940 prescriptions (19% major) After 6 errors in 978 prescriptions (0% major) Error rate reduced from 15% to 0.6% Marc Voeffray et al. Effect of computerisation on the quality and safety of chemotherapy prescription Qual. Saf. Health Care 2006;15;
4 Complex prescribing ideal target Narrow therapeutic index and highly toxic potential for harm is great Wide range of doses e.g. Methotrexate 10mg to 12g/m 2 Dose, interval, route varies with tumour type Dosed on BSA, weight, fixed Several medicines in most regimens Supportive medicines to deliver safely Multiple day treatment with different medicines on different days BEP Bleomycin D2, 8,15 Etoposide D1,2 3 Cisplatin D1, 2 Modifications for myelosuppression, renal + liver impairment frequent Common use of acronyms Classes of agents with very different uses e.g.rituximab/trastuzumab
5 Manual for Cancer Services National Drivers Rolling quality assurance programme for cancer services Purpose - enables quality improvement both in terms of clinical and patient outcomes % eprescribing Chemotherapy Services in England: Ensuring quality and safety National Chemotherapy Advisory Group 2009 Group established to advise DH on development + delivery of high quality chemotherapy services Handwritten prescriptions for parenteral chemotherapy should be replaced as soon as possible by pre-printed forms or, preferably, by fully validated electronic prescribing systems Chemotherapy measures S-139 to 142 Electronic Prescribing covers criteria for system and SOP s
6 Benefits and successes (1) Reduces prescription errors Legible Faster for complex treatment
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26 Benefits and Successes (2) Quality assurance Consistency of prescribing Controls access to protocol for certain diseases only Central control of change Set maximum doses/ routes that cannot be overwritten Reduces variation in clinical practice Template sign-off by consultant, 2 pharmacists Calculation of patient variables e.g. GFR, BSA
27 Benefits and Successes (3) Pharmacy specific Integrated worksheet and label preparation Automatic dose rounding RAPID RESPONSE REPORT NPSA/2008/RRR04 Doses of vinca alkaloids should be prepared for use by dilution in small volume intravenous bags, rather than in syringes
28
29 Additional benefits Audit and review of practice Identifies case series for research projects SACT dataset Facilitates service re-design Improves prescribing efficiency in clinic Easily accessible treatment view on admission
30 Specific Challenges/Limitations Reluctance/resistance to change Technophobes! Age range/ skills of staff across MDT Slower for simple treatments Training burden Find Clinical and Managerial Champions Employ national drivers Promote additional benefits Patience and perseverance! Time consuming start up/new staff/upgrades Level 1 competency (prescribing scenarios) Employ (if possible) a designated eprescribing lead
31 Specific Challenges/Limitations Loss of knowledge Errors Doses of chemotherapy never learned Supportive medicines not appreciated Teach and test the basics eprescribing = different errors NO errors If template incorrect - affects multiple patients Depends on quality of input e.g. 0mg/ height and weight mistakes Foster a quality culture Check and check again Review common themes
32 Specific Challenges/Limitations Technical challenges Difficult to set up templates for complex regimens Chronomodulation / trial dose bands National system unable to make many in-house tweaks No administration module paper copy for records Be creative, but maintain safety
33 Future Challenges Paper-lite Long established use of prescription as communication tool Reluctance to change Use clinical (multi-professional) champions Use local drivers efficiency Project group
Clinical Commissioning Policy: Chemotherapy Algorithms for Adults and Children. January 2013 Reference: NHS England XXX/X/X.
Clinical Commissioning Policy: Chemotherapy Algorithms for Adults and Children January 2013 Reference: NHS England XXX/X/X England 1 NHS England Clinical Commissioning Policy: Chemotherapy Algorithms for
More informationFAQ Document for Guidance on the Safe Use of Intrathecal Chemotherapy in the Treatment of Cancer
FAQ Document for Guidance on the Safe Use of Intrathecal Chemotherapy in the Treatment of Cancer Table of Contents Introduction... 1 Recommendation 31 FAQs... 2 Question 1.... 2 Answer... 2 Recommendation
More information1. Intrathecal must never be abbreviated to IT on a prescription form True / False
Appendix 1: Intrathecal SACT Assessment Questions Core General Questions must be completed by all staff. 1. Intrathecal must never be abbreviated to IT on a prescription form 2. Intrathecal SACT must be
More informationCHEMOTHERAPY NETWORK GROUP POLICY FOR ADMINISTRATION OF CYTOTOXIC CHEMOTHERAPY
CHEMOTHERAPY NETWORK GROUP POLICY FOR ADMINISTRATION OF CYTOTOXIC CHEMOTHERAPY Version 4.0 March 2016 Review date March 2018 Introduction It is the purpose of this policy to provide clear guidelines that
More informationGuidance for the Network Review of Chemotherapy Errors
Guidance for the Network Review of Chemotherapy Errors For approvals and version control see Document Management Record on page 8 Doc Ref: AngCN-CCG-C31 Approved and published: March 2013 Page 1 of 8 Table
More informationCommissioning Cancer Services. Andy McMeeking RCGP/NCIN Primary Care Workshop, 13 th February 2013
Commissioning Cancer Services Andy McMeeking RCGP/NCIN Primary Care Workshop, 13 th February 2013 The Health & Social Care Bill (27 th March 2012) Two New Organisations NHS Commissioning Board (NHS CB)
More informationIntrathecal. By the end of this chapter, you will be able to: Introduction. Chapter 20
Chapter 20 Intrathecal Preparations By the end of this chapter, you will be able to: l Describe the specific risks with intrathecal cytotoxic products l List five checks that need to be carried out on
More informationThe Newcastle upon Tyne Hospitals NHS Foundation Trust. Essential Out-of Hours Cancer Chemotherapy
The Newcastle upon Tyne Hospitals NHS Foundation Trust Essential Out-of Hours Cancer Chemotherapy Version No.: 4.0 Effective From: 27 December 2017 Expiry Date: 27 December 2020 Date Ratified: 19 July
More informationNorth of England Cancer Network. Policies and Procedures. Standards for the Safe Use of Oral Anticancer Medicines
\ North of England Cancer Network Policies and Procedures Standards for the Safe Use of Oral Anticancer Medicines NECN Oral Anticancer medicine Policy version 1.6 Page 1 of 17 Issue Date: Feb 2017 Contents
More informationNATIONAL CANCER CONTROL PROGRAMME. Oral Anti-Cancer Medicines Model of Care Recommendations
NATIONAL CANCER CONTROL PROGRAMME Oral Anti-Cancer Medicines Model of Care Recommendations National Cancer Control Programme Oral Anti-Cancer Medicines Model of Care Recommendations ISBN 978-1-78602-082-6
More informationto improve the collection and publication of data on chemotherapy activity, outcomes and costs, the chemotherapy dataset will be introduced
6.19... to improve the collection and publication of data on chemotherapy activity, outcomes and costs, the chemotherapy dataset will be introduced in April 2012 and this should provide commissioners,
More informationActivity Report April 2012 to March 2013
North, South East and West of Scotland Cancer Networks Brain/Central Nervous System Tumours National Managed Clinical Network Activity Report April 2012 to March 2013 Professor Roy Rampling Emeritus Professor
More informationActivity Report July 2012 June 2013
Urological Cancers Managed Clinical Network Activity Report July 2012 June 2013 Mr Seamus Teahan Consultant Urologist MCN Clinical Lead Tom Kane MCN Manager 1 CONTENTS EXECUTIVE SUMMARY 3 1. INTRODUCTION
More informationGuidance for Pharmacists on Safe Supply of Oral Methotrexate
Guidance for Pharmacists on Safe Supply of Oral Methotrexate Pharmaceutical Society of Ireland Version 2 January 2015 Contents 1. Introduction 2 2. Methotrexate 2 3. Guidance 2 3.1 Patient Review 2 3.2
More informationPROCEDURE REFERENCE NUMBER SABP/EXECUTIVE BOARD/0017/PROCEDURE15 PROCEDURE NAME MEDICINES PROCEDURE 15: METHOTREXATE
PROCEDURE REFERENCE NUMBER SABP/EXECUTIVE BOARD/0017/PROCEDURE15 PROCEDURE NAME MEDICINES PROCEDURE 15: METHOTREXATE BRIEF OUTLINE OF THIS PROCEDURE This procedure sets out the requirements for prescribing,
More informationA themed review of patient safety incidents involving anti-cancer medicines 1 November June 2008
A themed review of patient safety incidents involving anti-cancer medicines 1 November 2003 30 June 2008 October 2010 Executive Summary National Patient Safety Agency 2010. Copyright and other intellectual
More informationOPCS Classification of Interventions and Procedures Version 4.6 (April 2011)
Chemotherapy Regimens Clinical Coding Guidance OPCS-4.6 Version 1.0 Programme Sub Programme Data Standards & Products Clinical Classifications Document Record ID Key NPFIT-SHR-SHI-0318.01 Programme Director
More informationAdditional information to support. The National Patient Safety Agency s Rapid Response Report Risks of incorrect dosing of oral anti-cancer medicines
Additional information to support The National Patient Safety Agency s Rapid Response Report Risks of incorrect dosing of oral anti-cancer medicines Reference: NPSA/2008/RRR001 - issued on 22 January 2008
More informationECN Protocol Book. Generic Chemotherapy Protocol Guidelines. ECN_Protocol_Book_generic chemotherapy protocol guidelines guidelines_1
ECN Protocol Book Generic Chemotherapy Protocol Guidelines Name of person presenting document: Reason for document development: Names of development team: Specify groups of staff to whom the document relates:
More informationAndrew Heed, B. Pharm. CPIO, Integration Architect. The Newcastle upon Tyne Hospitals NHS Foundation Trust.
Andrew Heed, B. Pharm. CPIO, Integration Architect. The Newcastle upon Tyne Hospitals NHS Foundation Trust. Afroze Mobasher, Pharm. D Analyst Configurer Imperial College Healthcare NHS Trust Local reflection
More informationAdult Intravenous Systemic Anticancer Therapy (SACT) Section A. SUMMARY of SCHEME QIPP Reference
CA2 Nationally standardised Dose banding for Adult Intravenous Anticancer Therapy (SACT) Scheme Name CA2: Nationally Standardised Dose Banding for Adult Intravenous Systemic Anticancer Therapy (SACT) Section
More informationStRs and CT doctors in haematology. September Folinic acid dose modified.
High dose Methotrexate and folinic acid rescue Full Title of Guideline: Author (include email and role): Division & Speciality: Clinical Guideline Review Date September 2018 GUIDELINE FOR THE USE OF HIGH
More informationCancer and Data in the New NHS May Di Riley, Director Clinical Outcomes
Cancer and Data in the New NHS May 2011 Di Riley, Director Clinical Outcomes Overarching NHS context Financial constraints White Paper GP Commissioning/Commissioning Board Public Health England National
More informationChemotherapy Training and Assessment Policy. For Medical Prescribers and Pharmacy Verifiers
Chemotherapy Training and Assessment Policy For Medical Prescribers and Pharmacy Verifiers For approvals and version control see Document Management Record on page 6 Doc Ref: AngCN-CCG-C36 Approved and
More informationPharmaceutical risk management strategies for parenteral nutrition. J. Eastwood (UK)
ESPEN Congress Leipzig 2013 Pharmaceutical Session Pharmaceutical risk management strategies for parenteral nutrition J. Eastwood (UK) Pharmaceutical risk management strategies for parenteral nutrition
More informationGuideline for the Use of Granulocyte Colony Stimulating Factor (G-CSF) for Adults in Oncology and Haematology
(G-CSF) for Adults in Oncology and Haematology For Use in: By: Oncology and Haematology Inpatients and Outpatients Oncologists and Haematologists For: Division responsible for document: Key words: Name
More informationEducation and Training Strategy
ECN Pharmacy Group Education and Training Strategy Name of person presenting document: Reason for document development: Names of development team: Specify groups of staff to whom the document relates:
More informationCancer and Data in the New NHS May Di Riley, Director Clinical Outcomes
Cancer and Data in the New NHS May 2011 Di Riley, Director Clinical Outcomes Alignment with NHS reforms Improving outcomes: A strategy for cancer sets out how the future direction for cancer will be aligned
More informationNCCP Chemotherapy Regimen. Carboplatin (AUC 2) Weekly with Radiotherapy (RT)
INDICATIONS FOR USE: Carboplatin (AUC 2) Weekly with Radiotherapy (RT) Regimen Code 00419a *Reimbursement Indicator INDICATION ICD10 Chemoradiation treatment for stage III and IV locally advanced C11 nasopharyngeal
More informationNational Cancer Programme: Living With and Beyond Cancer
National Cancer Programme: Living With and Beyond Cancer Sarah Benger Senior Programme Manager, NHS England February 2017 Introduction: The Independent Cancer Taskforce Aim: To improve cancer services
More informationTesticular cancer and other germ cell tumours. London Cancer Jonathan Shamash
Testicular cancer and other germ cell tumours London Cancer 2018 Jonathan Shamash Background Testicular germ cell tumours are the commonest cancers of young men Overall they are curable but long term side
More informationeprescribing: Implementation reflections Andrew Heed Lead Pharmacist Clinical Informatics The Newcastle upon Tyne Hospitals NHS Foundation Trust
eprescribing: Implementation reflections Andrew Heed Lead Pharmacist Clinical Informatics The Newcastle upon Tyne Hospitals NHS Foundation Trust 3 Reflections eprescribing is: Simple, complicated, non-existent,
More informationconcentrate intravenous solution and other strong potassium solutions
Policy for the use of potassium chloride concentrate intravenous solution and other strong potassium solutions CLINICAL GUIDELINES ID TAG Policy for the use of potassium chloride Title: concentrate intravenous
More informationCARBOplatin (AUC5) and Etoposide 100mg/m 2 Therapy-21 day
INDICATIONS FOR USE: CARBOplatin (AUC5) and 100mg/m 2 Therapy-21 day ICD10 Regimen Code INDICATION Small cell lung cancer (SCLC) extensive disease C34 00271a *If a reimbursement indicator (e.g. ODMS, CDS
More informationInformatics in the new NHS : PHE and NCIN 9 months on. Nicky Coombes National Cancer Intelligence Network
Informatics in the new NHS : PHE and NCIN 9 months on. Nicky Coombes National Cancer Intelligence Network What was then... Key Funding Accountability Regulation Advice Parliament NICE Department of Health
More informationNCCP Chemotherapy Regimen. CARBOplatin (AUC7) and Etoposide- Autologous Conditioning Germ Cell Tumour Regimen
CARBOplatin (AUC7) and Etoposide- Autologous Conditioning Germ Cell INDICATIONS FOR USE: Regimen INDICATION ICD10 Code Treatment of metastatic relapsed/refractory germ cell tumours C62 00453a *Reimbursement
More informationDocument ref. no: Trust Policy and Procedure. PP(16)234 Prescribing, Dispensing and Administration of Methotrexate Policy
Document ref. no: Trust Policy and Procedure PP(16)234 Prescribing, Dispensing and Administration of Methotrexate Policy For use in: For use by: For use for: Document owner: Status: All Clinical Areas
More informationVIP (Etoposide, Ifosfamide and Cisplatin)
VIP (Etoposide, Ifosfamide and Cisplatin) Indication First line treatment for metastatic seminoma, non seminoma or combined tumours where bleomycin is contra-indicated. Usually used for patients with intermediate
More informationImproving Patient Safety and Compliance
Improving Patient Safety and Compliance Module 4 Includes Recommended Procedures Table of Contents Section A... 1 A.1 Intrathecal (IT) Doses... 1 Section B... 1 B.1 Vinca Alkaloids... 1 Section C... 2
More informationPPP 1. Continuation, modification, and discontinuation of a medication
PRESCRIBING POLICIES: 4.7 PHARMACIST AUTHORITY The College of Pharmacists of BC Professional Practice Policy (PPP) 58 Medication Management (Adapting a Prescription) became effective April 1, 2009. The
More informationA guide to essential gluten-free foods available from the pharmacy
A guide to essential gluten-free foods available from the pharmacy This information guide has been produced by For further information: This resource has been reviewed by the British Dietetic Association.
More informationWeekly Cisplatin + Radiotherapy - Interlace study -
Weekly Cisplatin + Radiotherapy - Interlace study - A phase III multicentre trial of weekly induction chemotherapy followed by standard chemoradiation versus standard chemoradiation alone in patients with
More informationJylamvo 2 mg/ml oral solution (Methotrexate) Guide for Healthcare Professionals. Information to minimise the risk of medication error
2 mg/ml oral solution (Methotrexate) Guide for Healthcare Professionals Information to minimise the risk of medication error NOTE: Special warnings and precautions for use - This oral solution contains
More informationProstate cancer timed clinical pathways
Prostate cancer timed clinical pathways December 2017 1 Context This document sets out preliminary best practice timed clinical pathways for prostate cancer. It is anticipated that Cancer Alliances will
More informationA three month project September December 2016
Improving Insulin Safety in the Clinical Decision Unit A three month project September December 2016 Sarah Gregory - In-Patient DSN, QEQM Hospital Julie Gammon - Ward Manager, CDU, QEQM Hospital 1 The
More informationCancer Outcomes and Services Dataset: Implications for clinical teams
Cancer Outcomes and Services Dataset: Implications for clinical teams Mick Peake Clinical Lead, NCIN National Clinical Lead, NHS Cancer Improvement Consultant & Senior Lecturer in Respiratory Medicine,
More informationCARBOplatin (AUC1.5) Chemoradiation Therapy-7 days
CARBOplatin (AUC1.5) Chemoradiation Therapy-7 days INDICATIONS FOR USE: Regimen Code INDICATION ICD10 Chemoradiation commencing 3 to 8 weeks after the completion of induction chemotherapy with TPF in patients
More informationAcute Oncology & Chemotherapy Clinical Network Group (CNG)
Acute Oncology & Chemotherapy Clinical Network Group (CNG) Work Programme 2014-2015 Version 1.0 This Work Programme has been agreed by: Title Name Date Agreed AO & Chemotherapy CNG Chair Ernie Marshall
More informationThe NHS Cancer Plan: A Progress Report
DEPARTMENT OF HEALTH The NHS Cancer Plan: A Progress Report LONDON: The Stationery Office 9.25 Ordered by the House of Commons to be printed on 7 March 2005 REPORT BY THE COMPTROLLER AND AUDITOR GENERAL
More informationUnited Kingdom and Ireland Association of Cancer Registries (UKIACR) Performance Indicators 2018 report
United Kingdom and Ireland Association of Cancer Registries (UKIACR) Performance Indicators 2018 report 20 June 2018 UKIACR Performance Indicators 2018 report 1 Contents Introduction... 3 Commentary for
More informationGuidelines for the use of G-CSF in the Department of Oncology
Guidelines for the use of G-CSF in the Department of Oncology Full Title of Guideline: Author (include email and role): Division & Speciality: Scope (Target audience, state if Trust wide): Review date
More informationService Level Agreement for the Provision of Level 1 Substance Misuse Services from a Community Pharmacy under contract to NHS Grampian
Service Level Agreement for the Provision of Level 1 Substance Misuse Services from a Community Pharmacy under contract to NHS Grampian 1. Introduction The provision of Substance Misuse (SM) services through
More informationCommissioning Chemotherapy Services Conference. Issues of consent in systemic therapy
Commissioning Chemotherapy Services Conference Issues of consent in systemic therapy Dr Janine Mansi Consultant Medical Oncologist 28 th November 2017 Introduction Background and context What we have done
More informationBleomycin, Etoposide and CISplatin (BEP) Therapy
Bleomycin, Etoposide and CISplatin (BEP) Therapy INDICATIONS FOR USE: INDICATION ICD10 Regimen Code Adjuvant treatment of high risk (vascular invasion C62 00300a carcinoma) stage 1 nonseminoma germ cell
More informationAUSTRALIAN AND NEW ZEALAND COLLEGE OF ANAESTHETISTS ABN
PS51 (2009) AUSTRALIAN AND NEW ZEALAND COLLEGE OF ANAESTHETISTS ABN 82 055 042 852 GUIDELINES FOR THE SAFE ADMINISTRATION OF INJECTABLE DRUGS IN ANAESTHESIA 1. INTRODUCTION 1.1 Current data suggest that
More informationCARBOplatin (AUC4-6) Monotherapy-21 days
INDICATIONS FOR USE: CARBOplatin (AUC4-6) Monotherapy-21 days INDICATION ICD10 Regimen Code First line adjuvant therapy of ovarian carcinoma of epithelial origin C56 00261a primary peritoneal carcinoma
More informationActivity Report March 2013 February 2014
West of Scotland Cancer Network Skin Cancer Managed Clinical Network Activity Report March 2013 February 2014 Dr Girish Gupta Consultant Dermatologist MCN Clinical Lead Tom Kane MCN Manager West of Scotland
More informationActivity Report April 2013 March 2014
North, South East and West of Scotland Cancer Networks Sarcoma National Managed Clinical Network Activity Report April 2013 March 2014 Dr Jeff White Consultant Oncologist NMCN Clinical Lead Lindsay Campbell
More informationStandard Operating Procedure for the Prevention and Treatment of Oral Mucositis
the Prevention and Treatment of Oral Mucositis Lead Author/Co-ordinator: Lisa MacLeod Specialist Clinical Pharmacist Haem/Onc UK Oral Mucositis in Cancer Group Signature: Reviewers: NCAG Signature: Approver:
More informationWHERE NEXT FOR CANCER SERVICES IN WALES? AN EVALUATION OF PRIORITIES TO IMPROVE PATIENT CARE
WHERE NEXT FOR CANCER SERVICES IN WALES? AN EVALUATION OF PRIORITIES TO IMPROVE PATIENT CARE EXECUTIVE SUMMARY Incidence of cancer is rising, with one in two people born after 1960 expected to be diagnosed
More informationWhat is Acute Oncology? Kay McCallum Acute Oncology Advanced Nurse Practitioner John Radcliffe Hospital Oxford September 2015
What is Acute Oncology? Kay McCallum Acute Oncology Advanced Nurse Practitioner John Radcliffe Hospital Oxford September 2015 What is Acute Oncology? Outline of Talk Concept of Acute Oncology Service (AOS)
More informationNational Cancer Peer Review Programme. Radiotherapy Service Evidence Guide
National Cancer Peer Review Programme Radiotherapy Service Evidence Guide Forward This evidence guide has been formulated to assist organisations in preparing for peer review. The contents of this guide
More informationUnderstanding value across pathways of care
Understanding value across pathways of care Donna Chung Head of Centre for Cancer Outcomes donna.chung@nhs.net Cancer Alliance Event 17 Jan 2018 Outline Overview of cancer landscape in north central and
More informationCardiac Rehabilitation: Costing Tool Guidance
Cardiac Rehabilitation: Costing Tool Guidance DH INFORMATION READER BOX Policy HR/Workforce Management Planning Clinical Estates Commissioning IM & T Finance Social Care / Partnership Working Document
More informationPVACE-BOP (Hodgkin s Lymphoma)
DRUG ADMINISTRATION SCHEDULE Day Drug Dose Route Diluent Rate 1 Ondansetron 8mg IV / Oral vinblastine 6mg/m 2 (Max: 10mg) IV Infusion Etoposide 100mg/m 2 IV infusion Patients over 65 years by 15 min infusion
More informationNCCP Chemotherapy Regimen. Obinutuzumab and Chlorambucil Therapy
INDICATIONS FOR USE: Obinutuzumab INDICATION ICD10 Regimen Code *Reimbursement Indicator Treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) and with comorbidities
More informationCandidate Information Sheet Therapeutic Decision Making Examination For Practice Ready Assessment (PRA) Selection Process
Candidate Information Sheet Therapeutic Decision Making Examination For Practice Ready Assessment (PRA) Selection Process For the purposes of the Therapeutics Decision-making (TDM) examination, therapeutics
More informationNational Breast Cancer Audit next steps. Martin Lee
National Breast Cancer Audit next steps Martin Lee National Cancer Audits Current Bowel Cancer Head & Neck Cancer Lung cancer Oesophagogastric cancer New Prostate Cancer - undergoing procurement Breast
More informationWest of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting
West of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting Definitions Acute nausea and vomiting Delayed nausea and vomiting Anticipatory nausea and vomiting Initial
More informationActivity Report July 2014 June 2015
Urological Cancers Managed Clinical Network Activity Report July 2014 June 2015 Mr Gren Oades Consultant Urologist MCN Clinical Lead Tom Kane MCN Manager CONTENTS EXECUTIVE SUMMARY 3 1. INTRODUCTION 5
More informationWeekly CARBOplatin (AUC2) PACLitaxel 50mg/m 2 Therapy with Radiotherapy
Weekly CARBOplatin (AUC2) PACLitaxel 50mg/m 2 with Radiotherapy INDICATIONS FOR USE: Regimen *Reimbursement INDICATION ICD10 Code Status Stage III Non small cell lung cancer (NSCLC) C34 00309a Hospital
More informationUsing MiCAL v18 (Medicines Information Computer Aided Learning) effectively
Using MiCAL v18 (Medicines Information Computer Aided Learning) effectively Contents 1. to MiCAL and MiDatabank... 3 2. What s in MiCAL... 3 Table 1: Case scenario titles, complexity, and clinical topic....
More informationIdentifying and reducing medication errors in mental health
Identifying and reducing medication errors in mental health Hilary Scott Chief Pharmacist South Essex Partnership University NHS Trust with valuable input from Ian Maidment, Senior Lecturer in Clinical
More informationNumber: III-45 Effective Date: 1 February 2012 Revised Date: November 2016
Page 1 of 8 RATIONALE The BCCA Compassionate Access Program (CAP) application process is intended to address the goals of the BCCA Systemic Therapy Treatment Policy Number III-40. It supports flexibility
More informationAn Integrated National Strategy for Breast Cancer Audit. Martin Lee Gill Lawrence
An Integrated National Strategy for Breast Cancer Audit Martin Lee Gill Lawrence National Audit Funding DH (NCAPOP* budget) Oversight National Clinical Audit Advisory Group (NCAAG) Commissioning and Monitoring
More informationGuideline scope Neonatal parenteral nutrition
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Guideline scope Neonatal parenteral nutrition The Department of Health in England has asked NICE to develop a new guideline on parenteral nutrition in
More informationOntario s Narcotics Strategy
Ontario s Narcotics Strategy Ontario Public Drug Programs Ministry of Health and Long-Term Care January 31, 2012 Ontario Harm Reduction Distribution Program Conference 2012 1 Background The Need for Action
More informationClinical Pharmacology and Therapeutics
Clinical Pharmacology and Therapeutics Updated on 23 Feb 2017 I) OBJECTIVES 1. To provide a broad training and in-depth experience at a level sufficient for trainees to acquire competence and professionalism
More informationLeeds: Early Diagnosis Project updates
Leeds: Early Diagnosis Project updates Cancer Cascade Event, 11 th May 2017 Joanna Bayton-Smith, Macmillan Leeds Cancer Strategy, Programme Manager Objectives: To provide overview of Leeds Cancer Strategy
More informationWorking with a Primary Care Trust (PCT) Caroline Hulett Health Promotion & Information Manager
Working with a Primary Care Trust (PCT) Caroline Hulett Health Promotion & Information Manager What we re going to cover Context: breast cancer in the UK and the importance of early diagnosis Background
More informationGemcitabine + Cisplatin Regimen
Gemcitabine + Cisplatin Regimen Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient Indication
More informationDepartment of Health & Human Services
Department of Health & Human Services Cancer Services Performance Indicators Round 1 2014 Report Department of Health & Human Services For further information please contact Kathryn Whitfield, Acting Manager,
More informationCosting report: Lipid modification Implementing the NICE guideline on lipid modification (CG181)
Putting NICE guidance into practice Costing report: Lipid modification Implementing the NICE guideline on lipid modification (CG181) Published: July 2014 This costing report accompanies Lipid modification:
More informationThe first stop for professional medicines advice. Community Pharmacy Oral Anticoagulant Safety Audit
Community Pharmacy Oral Anticoagulant Safety Audit This audit has been developed with help and support from the following organisations: Community Pharmacy Patient Safety Group PharmOutcomes Pharmaceutical
More informationImproving Value in Chemotherapy
Improving Value in Chemotherapy Nathan Hall March 2017 Content 1. Financial Context 2. What does Improving Value mean? 3. How can we Improve Value in Chemotherapy? 2 Our Context There is an ever increasing
More informationHaemato-oncology Clinical Forum. 20 th June 2013
Haemato-oncology Clinical Forum 20 th June 2013 Welcome Dr Majid Kazmi, LCA Haemato-oncology Pathway Group Chair Purpose of today Provide an update on progress of the LCA to date Identify priorities for
More informationCisplatin + Etoposide + Thoracic Radiotherapy (TRT) INDICATIONS FOR USE:
Cisplatin + Etoposide + Thoracic Radiotherapy (TRT) INDICATIONS FOR USE: Protocol INDICATION ICD10 Code Small cell lung cancer (SCLC) limited disease C34 00279a ELIGIBILTY: Indications as above ECOG 0-2
More informationNEW GENERAL MEDICAL SERVICES CONTRACT SPECIFICATION FOR THE PROVISION OF AN ENHANCED SERVICE SERVICE SPECIFICATION CHLAMYDIA SCREENING
NEW GENERAL MEDICAL SERVICES CONTRACT SPECIFICATION FOR THE PROVISION OF AN ENHANCED SERVICE SERVICE SPECIFICATION CHLAMYDIA SCREENING April 1, 2013 March 31, 2014 SERVICE CHLAMYDIA SCREENING REFERENCE
More informationNCCP Chemotherapy Protocol. Carboplatin Monotherapy-21 days
Carboplatin Monotherapy-21 INDICATIONS FOR USE: INDICATION ICD10 Protocol Code First line adjuvant therapy of ovarian carcinoma of epithelial origin primary peritoneal carcinoma fallopian tube cancer C56
More informationReducing the Door to Needle Time for Antibiotics in Suspected Neutropenic Sepsis using a Dedicated Clinical Pathway
Reducing the Door to Needle Time for Antibiotics in Suspected Neutropenic Sepsis using a Dedicated Clinical Pathway Dr Alex Williams, Oncology Specialty Doctor. Cheltenham General Hospital Oncology Centre
More informationTOP TIPS NHS COMMUNITY PHARMACY FLU VACCINATION SERVICE
TOP TIPS NHS COMMUNITY PHARMACY FLU VACCINATION SERVICE Top Tips NHS Community Pharmacy - Flu Vaccination Service ENSURE YOU ARE TRAINED AND COMPETENT TO DELIVER THE FLU SERVICE On 20th July 2015, PSNC
More informationCHEMOTHERAPY DISPENSING
CHEMOTHERAPY DISPENSING AUTOMATION: THE TAIWANESE EXPERIENCE 1 Sarah Lo MS, BCOP Oncology Pharmacy, Department of Pharmacy National Taiwan University Hospital Taipei, Taiwan. 2 BACKGROUND National Taiwan
More informationAn Oncology Digital Companion for Patient-Reported Outcomes with Electronic Health Record Integration. Dr Zachary Tan
An Oncology Digital Companion for Patient-Reported Outcomes with Electronic Health Record Integration Dr Zachary Tan A Diagnosis Of Cancer Is Devastating Shocked Confused Disorganized Alone The Digital
More informationFull title of guideline INTRAVENOUS VANCOMYCIN PRESCRIBING AND MONITORING GUIDELINE FOR ADULT PATIENTS. control
Full title of guideline Author: Contact Name and Job Title Division and specialty Scope Explicit definition of patient group to which it applies (e.g. inclusion and exclusion criteria, diagnosis) Changes
More informationUrgent Clinical Commissioning Policy Statement: Pembrolizumab for drug-resistant gestational trophoblastic neoplasia. NHS England Reference: P
Urgent Clinical Commissioning Policy Statement: Pembrolizumab for drug-resistant gestational trophoblastic neoplasia NHS England Reference: 170027P 1 Equality statement Promoting equality and addressing
More informationAcute Oncology: Service Provision in Smaller Cancer Centres Ernie Marshall Clatterbridge Centre for Oncology
Acute Oncology: Service Provision in Smaller Cancer Centres Ernie Marshall Clatterbridge Centre for Oncology Whiston Hospital St Helen s Hospital 350,000 population ~1000 beds Regional Plastics Unit DGH
More informationCancer Service Performance Indicators Round 1 Report. Integrated Cancer Services. January Department of Health
Cancer Service Performance Indicators 2013 Round 1 Report Integrated Cancer Services January 2014 Department of Health For further information please contact Kathryn Whitfield, Cancer Reform Manager Tel
More informationLondon Strategic Clinical Networks. My AKI. Guidance for patients with, or recovering from, acute kidney injury
London Strategic Clinical Networks My AKI Guidance for patients with, or recovering from, acute kidney injury Supporting the delivery of equitable, high quality AKI care through collaboration www.londonaki.net
More informationCreating an alert for GSK vaccines in e-mds EHR
Immunization Alerts in e-mds Ensure timely and appropriate immunization orders and administration Keeping track of patient vaccination requirements is an important aspect in the delivery of ongoing patient
More informationUnderstanding lymphoma: the importance of patient data
Understanding lymphoma: the importance of patient data Introduction what is a cancer registry and why is it important? Cancer registries collect detailed, personalised information and data about cancer
More information